deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT05744401

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants With Alzheimer's Disease

Sponsor: AbbVie

Interventions AL002
Updated 14 times since 2023 Last updated: Feb 6, 2026 Started: Jan 4, 2023 Primary completion: Jan 31, 2025 Completion: Feb 5, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.

A PHASE2 clinical study on Alzheimer's Disease, this trial is terminated or withdrawn. The trial is conducted by AbbVie and has accumulated 14 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Apr 2025 · 6 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

14 versions recorded
  1. Feb 2026 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Terminated PHASE2

  3. Apr 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Active Not RecruitingTerminated

  4. Oct 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

Show 9 earlier versions
  1. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  4. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE2

  5. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  6. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE2

  7. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  8. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  9. Mar 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Alector Inc.
Data source: Alector Inc.

For direct contact, visit the study record on ClinicalTrials.gov .